Pricing Log in Create free account

Cabaletta Bio, Inc. (CABA) vs Fate Therapeutics, Inc. (FATE)

Cabaletta Bio, Inc. and Fate Therapeutics, Inc. are both Biotechnology companies. Cabaletta Bio, Inc. is the larger, with a market value of $280.4M against $223.1M — 1.3× the size. Cabaletta Bio, Inc. has the higher net margin (0.00% vs −1,941.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Cabaletta Bio, Inc. leads on 6 and Fate Therapeutics, Inc. on 6.

Valuation

Metric CABA FATE Biotechnology median
P/E n/m n/m 10.60
P/S n/m 34.13 9.40
P/B 0.93 1.44 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.16 n/m 0.66
EV/Sales n/m 14.04 9.02
Earnings yield (120.77%) (57.07%) (32.88%)
Free cash flow yield (78.96%) (47.59%) (23.13%)

Profitability

Metric CABA FATE Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (2,058.08%) 0.00%
Net margin 0.00% (1,941.09%) 0.00%
Free cash flow margin 0.00% (1,624.06%) 0.00%
Return on equity (93.20%) (60.75%) (51.96%)
Return on assets (75.36%) (39.89%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CABA FATE Biotechnology median
Revenue growth (TTM) — (23.36%) 6.76%
EPS growth (last fiscal year) 10.26% 29.88% 29.88%
Revenue growth, 5-year CAGR — (26.71%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CABA FATE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.79 4.85 4.97
Net debt to EBITDA 0.84 1.47 1.01

Dividend

Metric CABA FATE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CABA FATE Biotechnology median
Market cap 280.44m 223.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack